Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Tarsus Pharmaceuticals, Inc
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
April 23, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Participate at Upcoming Investor Conferences
March 05, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
March 05, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Announces Pricing of $100.0 Million Public Offering
March 01, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Announces Proposed $100.0 Million Public Offering
February 29, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
February 27, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
February 22, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
February 20, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
January 31, 2024
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
December 11, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
November 09, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
November 01, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
September 06, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Present at Upcoming Investor Conferences
August 30, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
August 24, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
August 10, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
August 01, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
July 31, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis
July 25, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
June 12, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Present at the Jefferies Global Healthcare Conference
June 05, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements
May 09, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers
May 08, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Participate at the Bank of America 2023 Healthcare Conference
May 03, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer
April 24, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements
March 13, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus to Present at Upcoming Investor Conferences
March 02, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Added to NASDAQ Biotechnology Index
December 16, 2022
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
IBB
TARS
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
December 15, 2022
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements
November 09, 2022
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tickers
TARS
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.